Tumores mesenquimales diagnosticados en la unidad de gastroenterología del HMPC entre los años 2007 aL 2009

Se evaluaron las historias medicas con diagnostico de tumores mesenquimales confirmados por analisis inmunohistoquimico entre los anos 2007 y 2009. El objetivo fue describir a la poblacion segun caracteristicas clinicas, epidemiologicas, diagnosticos por imagenes y analisis anatomopatologico. Se obtuvieron 11 pacientes con diagnosticos de GIST(7), Leiomiomas(2), GANT(1) y Leiomiosarcoma(1). Del genero femenino (82%) y masculino (18%). Con un promedio de 55 anos de edad. Clinicamente presentaron dolor abdominal (45%), mareos (27%), pirosis (9%) y disfagia (1%). El 18% permanecio asintomatico. Entre los signos encontrados figuran: melena (36%), perdida de peso (27%), palidez cutanea (9%) y vomitos (9%). El 36% de los pacientes no presentaron hallazgos al examen fisico. Se realizo ultrasonido abdominal en el 100% de los pacientes, con hallazgos patologicos relacionados con el tumor en el 27 % de los casos. Al 90% de los pacientes se les realizo una Endoscopia Digestiva Superior, el 82% de los hallazgos se describieron como Tumores Submucosos y 9% se reporto como normal. Las lesiones se ubicaron en el estomago (60%), 27% en el intestino delgado ( duodeno y yeyuno); 9% en esofago y 9% en retroperitoneo. El ultrasonido endoscopico fue practicado al 82% de los pacientes, con un porcentaje de aciertos diagnosticos en el 90% de los tumores localizados en esofago, estomago e intestino delgado, y de 87,5% si se incluye el tumor retroperitoneal. La Tomografia Computada (TC) de abdomen fue practicada en 45% de los pacientes, con hallazgos patologicos en el 100% de los casos, descritos como Lesiones Ocupantes de Espacio (LOE), en estomago, intestino, esofago y retroperitoneo; y en el 20% de los pacientes se encontro enfermedad metastasica hepatica Recibieron tratamiento quirurgico el 82%, el 18% restante no se realizo por contraindicacion medica o se encuentran en espera del procedimiento. Y un 18% de los pacientes recibieron tratamiento medico con Imatinib... We evaluated the clinical records with a diagnosis of mesenchymal tumors confirmed by immunohistochemical analysis, from 2007 to 2009. The objective was to describe the population according to clinical and epidemiological features, diagnostic imaging and histopathological analysis. We found 11 patients with diagnoses of GIST(7), leiomyoma(2), leiomyosarcoma(1) and GANT(1); (82%) female and (18%) male, with a mean age of 55 years. They clinically presented abdominal pain (45%), dizziness (27%), heartburn (9%) and dysphagia (1%). 18% remained asymptomatic. Among the symptoms were: melena (36%), weight loss (27%), paleness (9%) and vomiting (9%). 36% of the patients had no findings at physical examination. Abdominal ultrasound was performed in 100% of the patients, with pathological findings related to the tumor in 27% of cases. In 90% of patients an upper digestive endoscopy was performed. 82% of findings were described as submucosal tumors and 9% was reported as normal. Lesions were located in stomach (60%); 27% in small bowel (duodenum and jejunum), 9% in esophagus and 9% in retroperitoneum. Endoscopic ultrasound was performed to 82% of patients, with a diagnostic accuracy of 90% for the tumors located in esophagus, stomach and small bowel; and 87,5% if the retroperitoneal tumor is included. The abdomen Computed Tomography (CT) was performed in 45% of patients with pathological findings in 100% of the cases, described as Space occupying lesion (SOL) in stomach, intestine, esophagus and retroperitoneum; and, in 20% of patients metastatic liver cancer was found. 82% received surgical treatment, the remaining 18% was not performed due to contraindication or are waiting for the procedure. And 18% of patients received medical therapy with Imatinib...